Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

BACKGROUND: GSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma. The objective of this study was to evaluate GSK2190915 efficacy, dose–response and safety in subjects with persistent asthma treated with short-acting beta2-agonists (SA...

Descripción completa

Detalles Bibliográficos
Autores principales: Follows, Richard MA, Snowise, Neil G, Ho, Shu-Yen, Ambery, Claire L, Smart, Kevin, McQuade, Barbara A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732081/
https://www.ncbi.nlm.nih.gov/pubmed/23682661
http://dx.doi.org/10.1186/1465-9921-14-54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732081/
https://www.ncbi.nlm.nih.gov/pubmed/23682661
http://dx.doi.org/10.1186/1465-9921-14-54

Ejemplares similares